Dustin J Maly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7225908/publications.pdf

Version: 2024-02-01

100	4,184	109321	133252
papers	citations	35 h-index	59 g-index

110	110	110	4775
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	One health therapeutics: Target-Based drug development for cryptosporidiosis and other apicomplexa diseases. Veterinary Parasitology, 2021, 289, 109336.	1.8	16
2	Pyrrolopyrimidine Bumped Kinase Inhibitors for the Treatment of Cryptosporidiosis. ACS Infectious Diseases, 2021, 7, 1200-1207.	3.8	3
3	ATP-competitive partial antagonists of the IRE1Î± RNase segregate outputs of the UPR. Nature Chemical Biology, 2021, 17, 1148-1156.	8.0	7
4	â€œExamining RAS pathway rewiring with a chemically inducible activator of RASâ€• Small GTPases, 2020, 11, 413-420.	1.6	5
5	Temporal and rheostatic control of genome editing with a chemically-inducible Cas9. Methods in Enzymology, 2020, 633, 119-141.	1.0	3
6	A chemically-controlled system for activating RAS GTPases. Methods in Enzymology, 2020, 633, 103-117.	1.0	0
7	The Right Tool for the Job: A Chemical and Genetic Toolkit for Interrogating DCLK1 Function. Cell Chemical Biology, 2020, 27, 1221-1223.	5.2	2
8	Comparative assessment of the effects of bumped kinase inhibitors on early zebrafish embryo development and pregnancy in mice. International Journal of Antimicrobial Agents, 2020, 56, 106099.	2.5	12
9	Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma. Cell Systems, 2020, 11, 196-207.e7.	6.2	24
10	How ATP-Competitive Inhibitors Allosterically Modulate Tyrosine Kinases That Contain a Src-like Regulatory Architecture. ACS Chemical Biology, 2020, 15, 2005-2016.	3.4	15
11	Suppression of unwanted CRISPR-Cas9 editing by co-administration of catalytically inactivating truncated guide RNAs. Nature Communications, 2020, 11, 2697.	12.8	42
12	Parallel Chemoselective Profiling for Mapping Protein Structure. Cell Chemical Biology, 2020, 27, 1084-1096.e4.	5.2	6
13	Kinobead/LC-MS Phosphokinome Profiling Enables Rapid Analyses of Kinase-Dependent Cell Signaling Networks. Journal of Proteome Research, 2020, 19, 1235-1247.	3.7	7
14	Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned. International Journal for Parasitology, 2020, 50, 413-422.	3.1	37
15	Development of a Chemical Toolset for Studying the Paralog-Specific Function of IRE1. ACS Chemical Biology, 2019, 14, 2595-2605.	3.4	16
16	Multi-input chemical control of protein dimerization for programming graded cellular responses. Nature Biotechnology, 2019, 37, 1209-1216.	17.5	59
17	Chemoproteomic Method for Profiling Inhibitor-Bound Kinase Complexes. Journal of the American Chemical Society, 2019, 141, 11912-11922.	13.7	11
18	P-Glycoproteinâ€“Mediated Efflux Reduces the In Vivo Efficacy of a Therapeutic Targeting the Gastrointestinal Parasite Cryptosporidium. Journal of Infectious Diseases, 2019, 220, 1188-1198.	4.0	7

#	Article	IF	Citations
19	Targeting Dynamic ATP-Binding Site Features Allows Discrimination between Highly Homologous Protein Kinases. ACS Chemical Biology, 2019, 14, 1249-1259.	3.4	20
20	Bumped kinase inhibitor 1369 is effective against Cystoisospora suis in vivo and in vitro. International Journal for Parasitology: Drugs and Drug Resistance, 2019, 10, 9-19.	3.4	12
21	A Combined Approach Reveals a Regulatory Mechanism Coupling Srcâ€™s Kinase Activity, Localization, and Phosphotransferase-Independent Functions. Molecular Cell, 2019, 74, 393-408.e20.	9.7	45
22	A Chemically Disrupted Proximity System for Controlling Dynamic Cellular Processes. Journal of the American Chemical Society, 2019, 141, 3352-3355.	13.7	16
23	Parallel Signaling through IRE1Î± and PERK Regulates Pancreatic Neuroendocrine Tumor Growth and Survival. Cancer Research, 2019, 79, 6190-6203.	0.9	25
24	Pharmacokinetics and In Vivo Efficacy of Pyrazolopyrimidine, Pyrrolopyrimidine, and 5-Aminopyrazole-4-Carboxamide Bumped Kinase Inhibitors against Toxoplasmosis. Journal of Infectious Diseases, 2019, 219, 1464-1473.	4.0	13
25	Small molecule inhibition of IRE1Î± kinase/RNase has anti-fibrotic effects in the lung. PLoS ONE, 2019, 14, e0209824.	2.5	51
26	Subcellular drug targeting illuminates local kinase action. ELife, 2019, 8, .	6.0	23
27	Kinome chemoproteomics characterization of pyrrolo[3,4-c]pyrazoles as potent and selective inhibitors of glycogen synthase kinase 3. Molecular Omics, 2018, 14, 26-36.	2.8	14
28	In vitro growth inhibition of Theileria equi by bumped kinase inhibitors. Veterinary Parasitology, 2018, 251, 90-94.	1.8	3
29	Toxoplasma Calcium-Dependent Protein Kinase 1 Inhibitors: Probing Activity and Resistance Using Cellular Thermal Shift Assays. Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	12
30	7H-Pyrrolo[2,3-d]pyrimidin-4-amine-Based Inhibitors of Calcium-Dependent Protein Kinase 1 Have Distinct Inhibitory and Oral Pharmacokinetic Characteristics Compared with 1H-Pyrazolo[3,4-d]pyrimidin-4-amine-Based Inhibitors. ACS Infectious Diseases, 2018, 4, 516-522.	3.8	5
31	Rheostatic Control of Cas9-Mediated DNA Double Strand Break (DSB) Generation and Genome Editing. ACS Chemical Biology, 2018, 13, 438-442.	3.4	13
32	Allosteric Modulation of JNK Docking Site Interactions with ATP-Competitive Inhibitors. Biochemistry, 2018, 57, 5897-5909.	2.5	9
33	Kinobead and Single-Shot LC-MS Profiling Identifies Selective PKD Inhibitors. Journal of Proteome Research, 2017, 16, 1216-1227.	3.7	36
34	Extended-spectrum antiprotozoal bumped kinase inhibitors: A review. Experimental Parasitology, 2017, 180, 71-83.	1.2	71
35	Two Novel Calcium-Dependent Protein Kinase 1 Inhibitors Interfere with Vertical Transmission in Mice Infected with Neospora caninum Tachyzoites. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	24
36	Development of a murine vertical transmission model for Toxoplasma gondii oocyst infection and studies on the efficacy of bumped kinase inhibitor (BKI)-1294 and the naphthoquinone buparvaquone against congenital toxoplasmosis. Journal of Antimicrobial Chemotherapy, 2017, 72, 2334-2341.	3.0	52

#	Article	IF	Citations
37	5-Aminopyrazole-4-Carboxamide-Based Compounds Prevent the Growth of Cryptosporidium parvum. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	17
38	Targeting ABL-IRE1Î± Signaling Spares ER-Stressed Pancreatic Î² Cells to Reverse Autoimmune Diabetes. Cell Metabolism, 2017, 25, 883-897.e8.	16.2	149
39	Bumped-Kinase Inhibitors for Cryptosporidiosis Therapy. Journal of Infectious Diseases, 2017, 215, 1275-1284.	4.0	52
40	In vitro efficacy of bumped kinase inhibitors against Besnoitia besnoiti tachyzoites. International Journal for Parasitology, 2017, 47, 811-821.	3.1	40
41	Advances in bumped kinase inhibitors for human and animal therapy for cryptosporidiosis. International Journal for Parasitology, 2017, 47, 753-763.	3.1	30
42	Rapidly inducible Cas9 and DSB-ddPCR to probe editing kinetics. Nature Methods, 2017, 14, 891-896.	19.0	88
43	Necessity of Bumped Kinase Inhibitor Gastrointestinal Exposure in Treating Cryptosporidium Infection. Journal of Infectious Diseases, 2017, 216, 55-63.	4.0	44
44	A computationally engineered RAS rheostat reveals RASâ€“ERK signaling dynamics. Nature Chemical Biology, 2017, 13, 119-126.	8.0	21
45	Profiling the Dual Enzymatic Activities of the Serine/Threonine Kinase IRE1Î±. Methods in Molecular Biology, 2017, 1513, 233-242.	0.9	1
46	Allosteric Modulation of Src Family Kinases with ATP-Competitive Inhibitors. Methods in Molecular Biology, 2017, 1636, 79-89.	0.9	2
47	Proteomic Profiling of Protein Kinase Inhibitor Targets by Mass Spectrometry. Methods in Molecular Biology, 2017, 1636, 105-117.	0.9	7
48	Reduced Activity of Mutant Calcium-Dependent Protein Kinase 1 Is Compensated in Plasmodium falciparum through the Action of Protein Kinase G. MBio, 2016, 7, .	4.1	37
49	Novel Bumped Kinase Inhibitors Are Safe and Effective Therapeutics in the Calf Clinical Model for Cryptosporidiosis. Journal of Infectious Diseases, 2016, 214, 1856-1864.	4.0	54
50	A novel protein kinase is essential in bloodstream Trypanosoma brucei. International Journal for Parasitology, 2016, 46, 479-483.	3.1	5
51	Selective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy. International Journal for Parasitology, 2016, 46, 871-880.	3.1	22
52	5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 5487-5491.	2.2	15
53	Development of an Orally Available and Central Nervous System (CNS) Penetrant Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitor with Minimal Human Ether-a-go-go-Related Gene (hERG) Activity for the Treatment of Toxoplasmosis. Journal of Medicinal Chemistry, 2016, 59, 6531-6546.	6.4	81
54	Structural and Functional Analysis of the Allosteric Inhibition of IRE1Î± with ATP-Competitive Ligands. ACS Chemical Biology, 2016, 11, 2195-2205.	3.4	75

#	Article	IF	Citations
55	Bumped kinase inhibitor prohibits egression in Babesia bovis. Veterinary Parasitology, 2016, 215, 22-28.	1.8	19
56	Conversion of a Single Polypharmacological Agent into Selective Bivalent Inhibitors of Intracellular Kinase Activity. ACS Chemical Biology, 2016, 11, 121-131.	3.4	23
57	Biochemical Screening of Five Protein Kinases from Plasmodium falciparum against 14,000 Cell-Active Compounds. PLoS ONE, 2016, 11, e0149996.	2.5	44
58	Radiotherapy Followed by Aurora Kinase Inhibition Targets Tumor-Propagating Cells in Human Glioblastoma. Molecular Cancer Therapeutics, 2015, 14, 419-428.	4.1	23
59	In Vitro and In Vivo Effects of the Bumped Kinase Inhibitor 1294 in the Related Cyst-Forming Apicomplexans Toxoplasma gondii and Neospora caninum. Antimicrobial Agents and Chemotherapy, 2015, 59, 6361-6374.	3.2	72
60	SAR Studies of 5-Aminopyrazole-4-carboxamide Analogues as Potent and Selective Inhibitors of Toxoplasma gondii CDPK1. ACS Medicinal Chemistry Letters, 2015, 6, 1184-1189.	2.8	32
61	Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection. Antimicrobial Agents and Chemotherapy, 2014, 58, 3547-3549.	3.2	66
62	The gatekeeper residue and beyond: homologous calcium-dependent protein kinases as drug development targets for veterinarian Apicomplexa parasites. Parasitology, 2014, 141, 1499-1509.	1.5	47
63	Potent and Selective Inhibitors of CDPK1 from T. gondii and C. parvum Based on a 5-Aminopyrazole-4-carboxamide Scaffold. ACS Medicinal Chemistry Letters, 2014, 5, 40-44.	2.8	49
64	Rapid profiling of protein kinase inhibitors by quantitative proteomics. MedChemComm, 2014, 5, 363-369.	3.4	20
65	A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation. Journal of Infectious Diseases, 2014, 209, 275-284.	4.0	83
66	SH2-Catalytic Domain Linker Heterogeneity Influences Allosteric Coupling across the SFK Family. Biochemistry, 2014, 53, 6910-6923.	2.5	20
67	Druggable sensors of the unfolded protein response. Nature Chemical Biology, 2014, 10, 892-901.	8.0	181
68	Bivalent inhibitors of protein kinases. Critical Reviews in Biochemistry and Molecular Biology, 2014, 49, 102-115.	5.2	52
69	Divergent Modulation of Src-Family Kinase Regulatory Interactions with ATP-Competitive Inhibitors. ACS Chemical Biology, 2014, 9, 1894-1905.	3.4	24
70	Allosteric Inhibition of the IRE1Î± RNase Preserves Cell Viability and Function during Endoplasmic Reticulum Stress. Cell, 2014, 158, 534-548.	28.9	384
71	Conformation-Selective ATP-Competitive Inhibitors Control Regulatory Interactions and Noncatalytic Functions of Mitogen-Activated Protein Kinases. Chemistry and Biology, 2014, 21, 628-635.	6.0	29
72	Development of potent and selective Plasmodium falciparum calcium-dependent protein kinase 4 (PfCDPK4) inhibitors that block the transmission of malaria to mosquitoes. European Journal of Medicinal Chemistry, 2014, 74, 562-573.	5.5	54

#	Article	IF	Citations
73	Neospora caninum Calcium-Dependent Protein Kinase 1 Is an Effective Drug Target for Neosporosis Therapy. PLoS ONE, 2014, 9, e92929.	2.5	63
74	Conformation-Selective Inhibitors Reveal Differences in the Activation and Phosphate-Binding Loops of the Tyrosine Kinases Abl and Src. ACS Chemical Biology, 2013, 8, 2734-2743.	3.4	30
75	Label Transfer Reagents to Probe p38 MAPK Binding Partners. ChemBioChem, 2013, 14, 209-216.	2.6	6
76	Active site profiling reveals coupling between domains in SRC-family kinases. Nature Chemical Biology, 2013, 9, 43-50.	8.0	53
77	A Hexylchloride-Based Catch-and-Release System for Chemical Proteomic Applications. ACS Chemical Biology, 2013, 8, 691-699.	3.4	17
78	Sequence Determinants of a Specific Inactive Protein Kinase Conformation. Chemistry and Biology, 2013, 20, 806-815.	6.0	77
79	A Novel Calcium-Dependent Protein Kinase Inhibitor as a Lead Compound for Treating Cryptosporidiosis. Journal of Infectious Diseases, 2013, 208, 1342-1348.	4.0	67
80	Investigating inactive conformations of protein kinases. FASEB Journal, 2013, 27, 1042.1.	0.5	0
81	Affinity-Based Probes Based on Type II Kinase Inhibitors. Journal of the American Chemical Society, 2012, 134, 19017-19025.	13.7	47
82	Targeting Diverse Signaling Interaction Sites Allows the Rapid Generation of Bivalent Kinase Inhibitors. ACS Chemical Biology, 2012, 7, 487-495.	3.4	26
83	Multiple Determinants for Selective Inhibition of Apicomplexan Calcium-Dependent Protein Kinase CDPK1. Journal of Medicinal Chemistry, 2012, 55, 2803-2810.	6.4	60
84	Development of Toxoplasma gondii Calcium-Dependent Protein Kinase 1 (TgCDPK1) Inhibitors with Potent Anti-Toxoplasma Activity. Journal of Medicinal Chemistry, 2012, 55, 2416-2426.	6.4	101
85	Divergent allosteric control of the IRE1Î± endoribonuclease using kinase inhibitors. Nature Chemical Biology, 2012, 8, 982-989.	8.0	175
86	Transmission of malaria to mosquitoes blocked by bumped kinase inhibitors. Journal of Clinical Investigation, 2012, 122, 2301-2305.	8.2	90
87	Label Transfer Reagents for the Study of Protein Kinase Complexes. FASEB Journal, 2012, 26, 755.3.	0.5	0
88	Bivalent inhibitors of the tyrosine kinases ABL and SRC: determinants of potency and selectivity. Molecular BioSystems, 2011, 7, 447-456.	2.9	12
89	Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4951-4955.	2.2	3
90	Affinity Reagents that Target a Specific Inactive Form of Protein Kinases. Chemistry and Biology, 2010, 17, 195-206.	6.0	36

#	Article	IF	Citations
91	Discovery of Potent and Selective Inhibitors of CDPK1 from C. parvum and T. gondii. ACS Medicinal Chemistry Letters, 2010, 1, 331-335.	2.8	126
92	A Small Molecule-Regulated Guanine Nucleotide Exchange Factor. Journal of the American Chemical Society, 2010, 132, 938-940.	13.7	24
93	Intracellular Delivery of Bioactive Molecules using Light-Addressable Nanocapsules. ACS Nano, 2010, 4, 7603-7611.	14.6	31
94	Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors. Nature Structural and Molecular Biology, 2010, 17, 602-607.	8.2	172
95	Equally Potent Inhibition of c-Src and Abl by Compounds that Recognize Inactive Kinase Conformations. Cancer Research, 2009, 69, 2384-2392.	0.9	134
96	A Chemical Genetic Method for Generating Bivalent Inhibitors of Protein Kinases. Journal of the American Chemical Society, 2009, 131, 6686-6688.	13.7	33
97	Design, synthesis and characterization of â€œclickableâ€•4-anilinoquinazoline kinase inhibitors. Molecular BioSystems, 2008, 4, 542.	2.9	10
98	Chemical Genomic and Proteomic Methods for Determining Kinase Inhibitor Selectivity. Combinatorial Chemistry and High Throughput Screening, 2007, 10, 652-666.	1.1	16
99	Exploring the Intermembrane Space. ACS Chemical Biology, 2007, 2, 213-216.	3.4	2
100	Protocol for rapidly inducible Cas9 and DSB-ddPCR. Protocol Exchange, 0, , .	0.3	2